Trial Profile

Enhanced Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists in Patients With Melanoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CDX 1140 (Primary) ; CDX 1140 (Primary) ; Melanoma vaccine (Primary) ; Melanoma vaccine (Primary) ; Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary)
Indications Malignant melanoma; Skin cancer; Uveal melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms Mel66

Most Recent Events

16 Jul 2024 Status changed from active, no longer recruiting to completed.
10 Oct 2023 Status changed from recruiting to active, no longer recruiting.
28 Sep 2020 Planned End Date changed from 1 Nov 2024 to 1 May 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com